论文部分内容阅读
目的:观察柴芪汤对非酒精性脂肪性肝病(NAFLD)大鼠肝脏固醇调节元件结合蛋白-1c(SREBP-1c)m RNA及蛋白表达的影响,探讨其防治NAFLD的可能机制。方法:将32只SPF级雄性SD大鼠随机分为正常组、模型组、柴芪汤组和罗格列酮组,每组8只,采用高脂高糖高盐饮食喂养8周复制NAFLD模型,造模第一天开始用药,给予柴芪汤[5.67g/(kg·d)]及罗格列酮混悬液[3 mg/(kg·d)]灌胃干预,8周后检测大鼠血清丙氨酸氨基转移酶(ALT)、天冬氨酸转氨酶(AST)、甘油三酯(TG)、胆固醇(TC)、高密度脂蛋白(HDL-C)、低密度脂蛋白(LDL-C)及肝组织中TG含量;观察肝组织病理形态改变;Western Blot测定肝SREBP-1c蛋白表达;RT-PCR测定肝SREBP-1c m RNA表达。结果:模型组大鼠血清ALT、AST、TC、TG、HDL-C、LDL-C水平及肝组织中TG含量明显高于正常组(P<0.05),2用药组各项指标低于模型组,差异有统计学意义(P<0.05);但2组间比较,差异无统计学意义(P>0.05)。2用药组SREBP-1c m RNA及蛋白表达水平较模型组降低,差异具有统计学意义(P<0.05),但2用药组比较差异无统计学意义(P>0.05)。结论:柴芪汤能够改善NAFLD大鼠肝脏脂肪变,其干预效果与西药罗格列酮相似,抑制SREBP-1c m RNA和蛋白表达,从而降低NAFLD大鼠血清ALT、AST、TG、TC、HLD-C、LDL-C,这可能是柴芪汤治疗NAFLD的机制之一。
Objective: To observe the effect of Chaiqi Decoction on the expression of hepatic steroid regulatory element binding protein-1c (SREBP-1c) m RNA and protein in non-alcoholic fatty liver disease (NAFLD) rats and to explore the possible mechanism of preventing and treating NAFLD. Methods: Thirty-two SPF male Sprague-Dawley rats were randomly divided into normal group, model group, chiqi decoction group and rosiglitazone group. Each group was fed with high fat, high sugar and high salt diet for 8 weeks to copy NAFLD model , The first day of the model began to take medication, give the Qichaq [5.67g / (kg · d)] and rosiglitazone suspension [3 mg / (kg · d)] intragastric intervention, Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), triglyceride (TG), cholesterol (TC), high density lipoprotein (HDL-C), low density lipoprotein (LDL- C) and the content of TG in liver tissue. The pathological changes of liver tissue were observed. The expression of SREBP-1c protein in liver was detected by Western Blot. The expression of SREBP-1c mRNA was detected by RT-PCR. Results: The serum levels of ALT, AST, TC, TG, HDL-C and LDL-C in the model group were significantly higher than those in the normal group (P <0.05). The indexes in the two groups were lower than those in the model group , The difference was statistically significant (P <0.05); but there was no significant difference between the two groups (P> 0.05). Compared with model group, the expression of SREBP-1c m RNA and protein in 2 groups were significantly decreased (P <0.05), but there was no significant difference between 2 groups (P> 0.05). CONCLUSION: Chaiqi decoction can improve hepatic steatosis in NAFLD rats. Its intervention effect is similar to western medicine rosiglitazone, inhibiting the expression of SREBP-1c m RNA and protein, thereby reducing the levels of ALT, AST, TG, TC and HLD -C, LDL-C, which may be one of the mechanisms of QIQI treatment of NAFLD.